Skip to main content

Table 2 Outcomes of patients in study group and historical group (n = 81)

From: Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

Characteristics

Study group

Historical group

P

Patients’ number

47

34

 

Cumulative incidence of relapse at 1 year (%)

22

56

<0.0001

Acute GvHD of grades 2–4 (%)

25

35

0.149

Acute GvHD of grade 3–4 (%)

11

15

0.366

Chronic GvHD (%)

52

33

0.039

Moderate or severe chronic GvHD (%)

49

23

0.005

TRM at 1 year (%)

9

6

0.064

LFS at 1 year (%)

71

35

<0.0001

Survival at 1 year (%)

78

44

<0.0001

Causes of mortality (n)

11

30

 

 Relapse (n)

7

25

 

 Infection (n)

3

3

 

 TMA (n)

1

0

 

 GvHD (n)

0

2

 
  1. GvHD graft-vs.-host disease, TRM treatment-related mortality, LFS leukemia-free survival, TMA thrombotic microangiopathy